Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M627Revenue $M55.5Net Margin (%)-50.6Altman Z-Score-1.1
Enterprise Value $M523EPS $-0.3Operating Margin %-38.7Piotroski F-Score6
P/E(ttm)--Beneish M-Score10.5Pre-tax Margin (%)-50.6Higher ROA y-yY
Price/Book50.110-y EBITDA Growth Rate %-26.9Quick Ratio7.5Cash flow > EarningsY
Price/Sales10.45-y EBITDA Growth Rate %-23.2Current Ratio7.6Lower Leverage y-yY
Price/Free Cash Flow22.1y-y EBITDA Growth Rate %--ROA % (ttm)-17.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-204.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M125ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with OREX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
OREXGeorge Soros 2012-06-30 Sold Out -0.03%$3.16 - $6.37
($3.76)
$ 5.0133%Sold Out0
OREXGeorge Soros 2012-03-31 Buy 0.03%$1.68 - $5.01
($3.11)
$ 5.0161%New holding500,000
OREXFirst Eagle Investment 2010-09-30 Sold Out -0.01%$3.9 - $6.77
($4.98)
$ 5.011%Sold Out0
OREXFirst Eagle Investment 2010-06-30 Add$4.05 - $7.04
($5.57)
$ 5.01-10%Add 74.07%470,000
OREXFirst Eagle Investment 2010-03-31 Add$5.9 - $7.66
($6.55)
$ 5.01-24%Add 22.73%270,000
OREXFirst Eagle Investment 2009-12-31 Add0.01%$6.44 - $9.39
($7.57)
$ 5.01-34%Add 83.33%220,000
OREXFirst Eagle Investment 2009-09-30 Buy 0.01%$5.2 - $10.34
($7.89)
$ 5.01-37%New holding120,000
OREXBill Gates 2009-06-30 Sold Out $1.89 - $5.21
($3.19)
$ 5.0157%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

OREX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


OREX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Booth Mark DChief Commercial Officer 2015-02-26Sell50,000$5.68-11.8 view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-12-02Sell22,643$6-16.5 view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-11-25Sell31,388$5.83-14.07 view
BOCK LOUIS CDirector 2014-11-18Buy1,325$5.58-10.22 view
BOCK LOUIS CDirector 2014-11-12Buy27,052$5.57-10.05 view
Turner Heather DVP, Gen. Counsel & Secretary 2014-09-22Sell300,000$4.4712.08 view
NARACHI MICHAELPresident and CEO 2014-09-15Buy50,000$4.784.81 view
Hagan Joseph PSr. VP, Corporate Development 2014-09-15Buy5,000$4.696.82 view
Hagan Joseph PChief Business Officer 2013-07-31Sell12,000$7.8-35.77 view
Booth Mark DChief Commercial Officer 2013-07-26Sell64,767$7.55-33.64 view

Press Releases about OREX :

    Quarterly/Annual Reports about OREX:

    News about OREX:

    Articles On GuruFocus.com
    Oxford Industries (OXM) Solid Growth Metrics, Orexigen Therapeutics (OREX) European Anti-Obesity App Mar 27 2015 
    Orexigen Therapeutics' Bright Future Mar 03 2015 
    Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
    Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
    Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
    Arena Facing Increased Pressure from Peers Apr 23 2012 
    Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
    Vivus Could Rocket on Success of Qnexa Apr 13 2012 
    Steve Cohen Bets On Orexigen Ahead of FDA Approval Jan 31 2011 
    Orexigen Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2010 

    More From Other Websites
    Orexigen CEO Pledged To Keep Data Secret, But Not From Himself May 20 2015
    OREXIGEN THERAPEUTICS, INC. Financials May 15 2015
    5 Key Takeaways From Orexigen's Earnings May 14 2015
    Drugmaker’s Very Bad Day Doesn’t Merit a Single Stock Downgrade May 14 2015
    Did Orexigen Have The Right To File Its Controversial Patent? May 14 2015
    OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events May 13 2015
    Macy's and Orexigen are big market movers May 13 2015
    Are Problems at Orexigen Still Just Getting Started? May 13 2015
    Orexigen Slumps as New Contrave Data Comes to Light - Analyst Blog May 13 2015
    Orexigen and Takeda Feud Over Cost of a Controversial Diet Drug Trial May 13 2015
    Biotech Stock Roundup: Alexion to Buy Synageva, FDA Panel Backs Vertex's Orkambi - Analyst Blog May 13 2015
    Orexigen Therapeutics (OREX) Stock Continues to Sink on Contrave Study Fallout May 13 2015
    Tuesday's After-Hours Movers: Vertex Pharmaceuticals, Orexigen Therapeutics And More May 12 2015
    Takeda Threatens to End Orexigen Partnership After Study Halted May 12 2015
    Orexigen Therapeutics Provides Statement on Termination of the Light Study and Updates on Contrave... May 12 2015
    Orexigen Therapeutics Provides Statement on Termination of the Light Study and Updates on Contrave... May 12 2015
    Orexigen Comments On Fallout From Data Release May 12 2015
    Orexigen Drops as Trial Shows Weight Pill Doesn’t Help Heart May 12 2015
    Orexigen Study for Diet Drug Ends Over Premature Data Disclosure May 12 2015
    Orexigen Therapeutics (OREX) Stock Declines After Halting Heart Benefit Tests May 12 2015
    Diet Drug Study Crashes And Burns In The Wake Of Leaked Results May 12 2015
    Orexigen Terminates Required Study for Diet Drug Contrave May 12 2015
    A Top Cardiologist Says A Diet Drug Maker Misled Patients And Investors May 12 2015
    Heart Benefit For Orexigen Drug Nearly Vanishes With New Data May 12 2015
    Takeda Pharmaceuticals and Orexigen Therapeutics Announce Termination of the Cardiovascular Outcomes... May 12 2015
    Orexigen Therapeutics to Speak at the Bank of America Merrill Lynch Health Care Conference May 08 2015
    Orexigen reports 1Q loss May 08 2015
    Orexigen Therapeutics to Host First Quarter 2015 Financial Results Conference Call May 05 2015
    Orexigen Announces Receipt of Paragraph IV Certification Notice Apr 22 2015
    Orexigen Therapeutics to Speak at the Needham Healthcare Conference Apr 10 2015
    Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer Mar 30 2015
    US pre-open: Futures point to another day in the red ahead of Yellen's speech Mar 27 2015
    Ahead of the Bell: Orexigen shares rise Mar 27 2015
    Orexigen gets approval to market weight loss drug in Europe Mar 26 2015
    Ahead of the Bell: Orexigen Therapeutics shares retreat Mar 06 2015
    Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31,... Feb 25 2015
    Orexigen misses 4Q profit forecasts Feb 25 2015
    Orexigen Therapeutics to Speak at the 2015 RBC Capital Markets Global Healthcare Conference Feb 23 2015
    Orexigen Therapeutics to Host Full Year and Fourth Quarter 2014 Financial Results Conference Call... Feb 20 2015
    Orexigen Therapeutics to Present at the J.P. Morgan 2015 Healthcare Conference Jan 08 2015
    Orexigen's Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP... Dec 19 2014
    Orexigen Therapeutics to Present at the Piper Jaffray Healthcare Conference Nov 26 2014
    Orexigen Announces Allowance of New U.S. Patent for Contrave® (naltrexone HCl / bupropion HCl... Nov 21 2014
    Orexigen rises as weight loss drug review proceeds Nov 10 2014
    Orexigen Therapeutics Reports Results for the Third Quarter Ended September 30, 2014 Nov 10 2014
    Orexigen Therapeutics to Present at the Credit Suisse Healthcare Conference Nov 06 2014
    Orexigen Therapeutics to Host Third Quarter 2014 Financial Results Conference Call and Webcast Nov 04 2014
    Orexigen Announces Contrave® (naltrexone HCI and bupropion HCI extended release) Data Presentations... Oct 31 2014
    Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI)... Oct 20 2014
    Milestone Payments Earned by Orexigen Total $100 Million as Contrave® (naltrexone HCI and bupropion... Oct 15 2014
    FDA approves weight-loss drug Contrave Sep 11 2014
    Orexigen falls on further FDA delays for diet pill Jun 11 2014
    Ahead of the Bell: Orexigen Therapeutics slips Jun 11 2014
    MARKET PULSE-Biofuel, Orexigen, Rambus, Synaptics Jun 11 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK